<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/251ADAA2-674C-4D0D-944F-5C6E42310B93"><gtr:id>251ADAA2-674C-4D0D-944F-5C6E42310B93</gtr:id><gtr:firstName>Inderjeet</gtr:firstName><gtr:surname>Dokal</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FBC7DD3D-C15E-4DFE-8006-C378116302B4"><gtr:id>FBC7DD3D-C15E-4DFE-8006-C378116302B4</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Casimir</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400534"><gtr:id>3C36E33D-0C89-41D1-AC51-0CEE38E3B7FE</gtr:id><gtr:title>In vitro correction of the premature ageing syndrome, dyskeratosis congenita, by retroviral mediated gene transfer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400534</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Dykeratosis congenita (DC) is a severe inherited condition characterised by bone marrow failure, muco-cutaneous abnormalities and an increased predisposition to malignancy. The main cause of premature mortality in DC is aplastic anaemia (bone marrow failure). Current treatment is essentially limited to the use of bone marrow transplantation from a matched sibling donor; in most situations this will not be a treatment option. The recent identification of two of the genes mutated in DC (DKC1 and TERC) makes DC now an attractive candidate disorder for gene therapy. In particular, evidence suggests that phenotypically corrected cells should possess a growth advantage over affected cells. DC shares this characteristic with inherited immunodeficiency (X-SCID), in which successful retroviral mediated gene therapy is now a clinical reality. 

We will use retroviral vectors to transduce DC-patient B cell lines and cells obtained directly from peripheral blood and bone marrow. The B cells lines will be assessed for correction of the DC defect by analysis of cell proliferation, apoptosis and telomerase activity. Primary cells will be analysed by standard haemopoietic colony assay and a haemopoietic progenitor self-renewal assay (CFU-GM re-plating). In addition, we will investigate transduction of murine embryonal stem (ES) cells, in which the gene affected in X-linked DC (dyskerin) has been inactivated. These latter experiments should help us to better define the precise criteria required for a positive therapeutic outcome in DC patients. 

The results of gene transfer into these different cell types will enable us to determine the optimal conditions for delivering haemopoietic gene therapy in DC and aplastic anaemia patients. These studies may also facilitate the development of gene therapy for other haematological disorders such as sickle cell disease and thalassaemia. Finally, they will provide a unique opportunity to determine whether telomere rejuvenation is possible in humans and if this results in amelioration of disease features.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>375234</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In-vitro correction of the dyskeratosis congenita defect</gtr:description><gtr:id>BB5D1029-CB9F-448E-B38D-9852A04CE3C5</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>140EEA05F4A</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cell line (EBV)</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>130AE003-F2CE-41FB-B859-8B8A4347614C</gtr:id><gtr:title>Circulating haematopoietic progenitors are differentially reduced amongst subtypes of dyskeratosis congenita.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ed3b32c6522598d2a66a776cf6e7a61"><gtr:id>7ed3b32c6522598d2a66a776cf6e7a61</gtr:id><gtr:otherNames>Kirwan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>13BB3B8D5DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D31102C0-C9D6-4FA1-927E-24DD5AB50048</gtr:id><gtr:title>Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ed3b32c6522598d2a66a776cf6e7a61"><gtr:id>7ed3b32c6522598d2a66a776cf6e7a61</gtr:id><gtr:otherNames>Kirwan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>C83BDAE78BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA57B02F-9C56-416F-BBE7-0E4DE11A59F3</gtr:id><gtr:title>Single-molecule analysis of the human telomerase RNA.dyskerin interaction and the effect of dyskeratosis congenita mutations.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cf52b5bca0cdad766d66910a3e9f64c"><gtr:id>0cf52b5bca0cdad766d66910a3e9f64c</gtr:id><gtr:otherNames>Ashbridge B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>14EC1446606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFF88D28-6DD6-43EF-8448-D48936EAA9BE</gtr:id><gtr:title>Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ed3b32c6522598d2a66a776cf6e7a61"><gtr:id>7ed3b32c6522598d2a66a776cf6e7a61</gtr:id><gtr:otherNames>Kirwan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>4AC62C4F085</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400534</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>